SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNBP - Nanobac Pharmaceuticals Inc. (Bulls Board)
NNBP 0.00010000.0%Oct 31 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: da_cheif™9/12/2006 10:17:03 AM
   of 106
 
Wall Street Resources, Inc. Releases an Analytical Profile on Nanobac Pharmaceuticals, Inc. with 12-Month Target Value of $0.91

TAMPA, Fla., Sep 12, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company") today announced the release of an analytical profile on the Company, by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.

The free report is available at: wallstreetresources.net. The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks. Wall Street Resources, Inc. is a professional research and consulting firm with over 10 years of experience providing analysis for emerging growth companies and information to the investment community.

"We are very excited that Wall Street Resources has seen fit to issue an overall evaluation of our company, and with a short-term target value of $0.91 per share. Our management team and scientists have worked very hard to become the leader in Calcifying Nanoparticles (CNPs), and we consider this report to be verification that our management team is on track," stated John Stanton, CEO of Nanobac Pharmaceuticals. "The quality of Mr. Silver's research, coupled with the comprehensive analysis of our business plan, will assist the Company in gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmceuticals, Inc."

Mr. Silver stated, "Nanobac's extensive body of scientific research in the study of Calcifying Nanoparticles represents a paradigm shift in the understanding of calcific disease. We believe that Nanobac's developments of diagnostic and therapeutic products will revolutionize the medical industry. With the market for calcific diseases currently exceeding $500 billion per year, we believe that the commercial opportunities for Nanobac's products are virtually limitless."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext